Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY
Alnylam Pharmaceuticals — Clinical Trials on Alzheimer's Disease (CTAD) Conference 2024
21 slides from Alnylam Pharmaceuticals's conference presentation, Nov 1, 2024
Slide 1: Design and Rationale of cAPPricorn-1, a Phase 2 Study of Mivelsiran in CAA
Design and Rationale of cAPPricorn-1, a Phase 2 Study of Mivelsiran in Patients with Cerebral Amyloid Angiopathy Jin-Moo Lee1, Ellis S. van Etten2, Matthijs J. P. van Osch2, Catharina J. M. Klijn3, Alexandre Sostelly4, Sasikiran Goteti4, Farshid Sepehrband5, Andreja Avbersek5, Robert W. Deering4, Ne
Slide 2: Disclosures
Disclosures Presenter: Jin-Moo Lee, MD, PhD Conflict Disclosure NIH R01NS120481, R37NS110699, UFNS125512, Research Support RF1NS139970, R01NS120481, RF1AG079503 Unpaid Advisory Committee Member Alnylam Pharmaceuticals Mivelsiran: Mivelsiran is an investigational drug being studied for the treatment
Slide 3: CAA and AD are Distinct but Related Diseases Linked by Aβ
CAA and AD are Distinct but Related Diseases Linked by Aβ In CAA, Progressive Aβ Accumulation Leads to Vascular Disease, Debilitating Strokes, and Cognitive Decline • Cerebral amyloid angiopathy (CAA) is characterized by progressive deposition of Aβ in cerebral blood vessels1 • Manifestations includ
Slide 4: Aβ Precursor Protein (APP) is the Source of Aβ
Aβ Precursor Protein (APP) is the Source of Aβ Aβ is Derived from APP and is Deposited in Vessels APP Structure8,a • APP is a transmembrane protein that is cleaved to produce a variety of peptides, including Aβ1 • Vascular amyloid deposits are largely composed of Aβ40, and parenchymal plaques are mo
Slide 5: RNA Interference Harnesses an Endogenous Process to Lower Expression of Disease-Associated Proteins
RNA Interference Harnesses an Endogenous Process to Lower Expression of Disease-Associated Proteins Such as APP • RNA interference (RNAi) is a natural RNAi Mechanism of Action3,a process that regulates gene expression1 Synthetic gene-specific siRNA • Synthetic small interfering RNAs (siRNAs) are des
Slide 6: Intrathecal Delivery of C16-Conjugated siRNA Enables CNS Targeting in Preclinical Models
Intrathecal Delivery of C16-Conjugated siRNA Enables CNS Targeting in Preclinical Models, Supporting Clinical Development • In preclinical models, intrathecally administered C16-conjugated siRNA enabled distribution throughout the CNS and durable target engagement in the deep brain,1 supporting deve
Slide 7: Mivelsiran is an Investigational RNAi Therapeutic Designed to Reduce APP Production in the CNS
Mivelsiran is an Investigational RNAi Therapeutic Designed to Reduce APP Production in the CNS Mivelsiran is Being Evaluated in AD and in CAA Phase 1 Early-Onset AD Single and Multiple Ascending Dose Study (ongoing)1 AD (e.g., early-onset AD, autosomal dominant AD, Down syndrome AD) Phase 2 CAA cAPP
Slide 8: Single Doses of Mivelsiran Reduced CSF sAPPβ and Aβ40 in a Phase 1 Study
Single Doses of Mivelsiran Reduced CSF sAPPβ and Aβ40 in a Phase 1 Study of Patients With Early-Onset ADa,1 sAPPβ Aβ40 Mivelsiran has shown robust and durable reductions of amyloidogenic proteins in early-onset AD, supporting its further evaluation in CAA1,2 NCT05231785. Data shown as of August 2, 2
Slide 9: Phase 1 Safety Profile in Patients with Early-Onset AD Supports Continued Development
Phase 1 Safety Profile in Patients with Early-Onset AD Supports Continued Development of Mivelsiran1 Mivelsiran 25 mg Mivelsiran 35 mg Mivelsiran 50 mg Mivelsiran 75 mg Patients with events or placebo or placebo or placebo or placebo (N=6, PY=6.9) (N=8, PY=4.8) (N=8, PY=7.6) (N=14, PY=13.5) Time fro
Slide 10: Mivelsiran Phase 1 and Phase 2 Development Overview
Mivelsiran Phase 1 and Phase 2 Development Overview Phase 1 Early-Onset AD Early-Onset Alzheimer’s Disease Single and Multiple Ascending Dose Study (ongoing)1 AD (e.g., early-onset AD, autosomal dominant AD, Down syndrome AD) Phase 2 CAA cAPPricorn-1: Phase 2 study in sporadic and Dutch-type CAA2 AD
Slide 11: cAPPricorn-1 is a Phase 2 Study in Sporadic or Hereditary CAA
cAPPricorn-1 is a Phase 2 Study Evaluating Mivelsiran in Patients with Sporadic or Hereditary CAA Sporadic CAA Dutch-type CAA Rationale: Rationale: • High prevalence, later onset • Rapidly progressive, genetically defined • Significant unmet need to reduce risk of hemorrhagic • Earlier onset with fe
Slide 12: cAPPricorn-1 Study Design
cAPPricorn-1 Study Design Phase 2 Multiple-Dose Study Evaluating Efficacy, Safety, and Pharmacodynamics Sporadic CAAa R (Primary Efficacy Cohort) Mivelsiran IT Safety Mivelsiran IT follow-up Placebo IT Dutch-type CAAa R (Descriptive Cohort) Double-Blind Treatment Period Optional Open-Label Extension
Slide 13: cAPPricorn-1 will Evaluate Complementary Hemorrhagic and Non-Hemorrhagic Outcome Measures
cAPPricorn-1 will Evaluate Complementary Hemorrhagic and Non-Hemorrhagic Outcome Measures Efficacy will be Assessed up to 24 Months and Safety up to 48 Months Measure Description Annualized rate of new lobar cerebral microbleeds on MRI Primary Endpointa Novel global rank endpoint integrating clinica
Slide 14: cAPPricorn-1 Overall Study Design
cAPPricorn-1 Overall Study Design A Phase 2 Multiple-Dose Study Evaluating Efficacy, Safety, and Pharmacodynamics of Mivelsiran in Patients with CAA Study Population (N~200) Sporadic CAA Cohort Outcome Measuresa • Age ≥50 years Primary endpoint Sporadic • Probable CAA (Boston v2.0 Annualized rate of
Slide 15: Summary
For US HCPs Only Scan to View Congress Summary Material Presented For non-US HCPs, please contact [email protected] • CAA is characterized by cerebrovascular deposition of Aβ and is commonly comorbid with AD1,2 − CAA increases the risk of hemorrhagic strokes and independently contributes to progre
Slide 16: Thank you to the patients, investigators and collaborators
Thank you to the patients, their families, investigators, study staff, collaborators, and the Global Steering Committee for their support and participation in the ongoing cAPPricorn-1 study
Slide 17: Back Up
| || Back Up
Slide 18: RNAi and ASO Therapeutics are Distinct Classes of Medicine
RNAi and ASO Therapeutics are Distinct Classes of Medicine1 RNAi ASO Double- Activated siRNA–RISC– Degraded stranded siRNA guide strand Active complex fully RISC mRNA complex mRNA siRNA remains bound to dissociates after RNAi Nature of RISC and further cleavage;3,5 Interaction processes target recru
Slide 19: Mivelsiran is an Investigational RNAi Therapeutic Designed to Reduce APP Production in the CNS
Mivelsiran is an Investigational RNAi Therapeutic Designed to Reduce APP Production in the CNS • Intrathecally administered C16- Therapeutic Hypothesis of Mivelsiran in CAA conjugated siRNA enables cellular Nucleus APP gene uptake in the CNS1 • Reducing production of APP is expected to lower Aβ pept
Slide 20: A Phase 1 Study Evaluating Safety and Efficacy of Single Ascending Doses of Mivelsiran
A Phase 1 Study Evaluating Safety and Efficacy of Single Ascending Doses of Mivelsiran in Early-Onset AD1 An Ongoing, Double-Blind, Placebo-Controlled Study Primary Endpoint N=6 25 mg mivelsiran or placebo (randomized 2:1) Study Population (N=36) • Safety and tolerability (frequency of AEs) Adult pa
Slide 21: Single Doses of Mivelsiran Reduced CSF sAPPα and Aβ42 in a Phase 1 Study
Single Doses of Mivelsiran Reduced CSF sAPPα and Aβ42 in a Phase 1 Study of Patients With Early-Onset AD1 sAPPα Aβ42 Mivelsiran has shown robust and durable reductions of APP cleavage products in early-onset AD, supporting its further evaluation in CAA1,2 NCT05231785. Data shown as of August 2, 2024
Alnylam Pharmaceuticals — Clinical Trials on Alzheimer's Disease (CTAD) Conference 2024 on 6ix